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Abstract It has recently been proposed that a three-gene
model (SCMGENE) that measures ESR1, ERBB2, and
AURKA identifies the major breast cancer intrinsic sub-
types and provides robust discrimination for clinical use in
a manner very similar to a 50-gene subtype predictor
(PAM50). However, the clinical relevance of both predic-
tors was not fully explored, which is needed given that
a *30 % discordance rate between these two predictors
was observed. Using the same datasets and subtype calls
provided by Haibe-Kains and colleagues, we compared the
SCMGENE assignments and the research-based PAM50
assignments in terms of their ability to (1) predict patient
outcome, (2) predict pathological complete response (pCR)
after anthracycline/taxane-based chemotherapy, and (3)
capture the main biological diversity displayed by all genes
from a microarray. In terms of survival predictions, both
assays provided independent prognostic information from
each other and beyond the data provided by standard clini-
cal–pathological variables; however, the amount of prog-
nostic information was found to be significantly greater with
the PAM50 assay than the SCMGENE assay. In terms of
chemotherapy response, the PAM50 assay was the only
assay to provide independent predictive information of pCR
in multivariate models. Finally, compared to the SCMGENE
predictor, the PAM50 assay explained a significantly greater
amount of gene expression diversity as captured by the two
main principal components of the breast cancer microarray
data. Our results show that classification of the major and
clinically relevant molecular subtypes of breast cancer are
best captured using larger gene panels.
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Introduction
Over the years, global gene expression analyses have
identified at least four intrinsic subtypes of breast cancer
(Luminal A, Luminal B, HER2-enriched, and Basal-like)
and a normal-like group with significant differences in
terms of their risk factors, incidence, baseline prognoses
and responses to systemic therapies [1–4]. In 2009, we
reported a clinically applicable gene expression-based
predictor that robustly identifies these main intrinsic sub-
types by quantitative measurement of 50 genes (i.e.,
PAM50) [1]. Identification of these molecular subtypes
using pathology-based surrogate definitions based upon
hormone receptors (HRs), HER2 and Ki-67 expressions has
been adopted by the 2011 St. Gallen Consensus Conference
for treatment decision-making in early breast cancer [5],
however, controversy exists as to whether these complex
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molecular subtypes can be effectively captured using four
or less biomarkers.
Recently, Haibe-Kains et al. [6] reported a mRNA
expression predictor that classifies tumors into four molec-
ular entities (ER?/HER2-/Low Proliferative, ER?/
HER2-/High Proliferative, HER2? and ER-/HER2-) by
quantitative measurement of three genes (ESR1, ERBB2 and
AURKA). Similar to the PAM50 subtype predictions, the
molecular entities identified by the SCMGENE predictor
were found significantly associated with survival outcome
[6]. However, a direct head-to-head comparison between
both predictors was not performed despite that fact that the
concordance (i.e., j score) between these two predictors was
0.59 (0.58–0.61), which is considered moderate agreement
and similar to the j scores obtained when histological grade
is evaluated by two independent observers [7].
In this study, we compared the SCMGENE assignments
and the research-based PAM50 assignments in terms of their
ability to (1) predict patient outcome, (2) predict pathologi-
cal complete response (pCR) after anthracycline/taxane-
based chemotherapy, and (3) capture the main biological
diversity displayed by all genes from a microarray.
Materials and methods
Clinical and gene expression data
We used the clinical (Supplemental file: jnci-JNCI-11-
0924-s02.csv) and gene expression data (http://www.comp
bio.dfci.harvard.edu/pubs/sbtpaper/data.zip) as provided by
Haibe-Kains et al. [6]. For survival predictions, we used
distant metastasis-free survival as the endpoint since it
provides the largest number of patients that can be evalu-
ated across 13 datasets (CAL [8], EMC2 [9], DFHCC [10],
MAINZ [11], MDA5 [12], MSK [13], NKI [14], TAM
[15], TRANSBIG [16], UCSF [17], UNT [18], VDX [19]
and VDX3 [20]). None of the datasets (or samples) used for
survival (or response prediction) were used to derive the
SCMGENE or the PAM50 subtype predictor.
To compare chemotherapy response data, we used the
clinical data of one of the datasets (MAQC2 [GSE20194]
[21]) evaluated by Haibe-Kains et al. [6], which is com-
posed of 230 pre-treatment samples with annotated
response data (pCR vs. residual disease [RD]) after neo-
adjuvant anthracycline/taxane-based chemotherapy. Sam-
ples that received trastuzumab were excluded.
Combined microarray dataset
Eighteen Affymetrix and Agilent-based datasets (CAL [8],
DFHCC [10], DUKE [22], EORTC10994 [23], EXPO [24],
KOO [25], MAINZ [11], MAQC2 [21], MDA4 [26], MSK
[13], NKI [14], PNC [27], STK [28], TRANSBIG [16],
UNC337 [29], UNT [18], UPP [30] and VDX [19]) as pro-
vided in Haibe-Kains et al. [6] and with an appropriate dis-
tribution of ER? (50–90 %, as defined by IHC) versus ER-
tumors were combined into a single gene expression matrix.
Probes mapping to the same gene (Entrez ID as defined by
the manufacturer) were averaged to generate independent
expression estimates. In each cohort, genes were median
centered and standardized to zero mean and unit variance.
Statistical analyses
Distant metastasis-free survival univariate and multivariate
analysis were calculated using a Cox proportional regres-
sion model. Likelihood ratio statistics of subtypes defined
by the PAM50 or the SCMGENE predictors were also
evaluated after accounting for clinical–pathological vari-
ables (age at diagnosis, nodal status, and tumor size) and
type of systemic adjuvant treatment (chemotherapy,
endocrine, and none). Models were first conditioned on one
predictor and the clinical–pathological variables, and then
the significance of the other was tested. Chemotherapy
response (pCR vs. RD) predictions of each variable were
evaluated using univariate and multivariate logistic
regression analyses. Finally, R2 values of each predictor
(SCMGENE or PAM50) for each principal component
(PC) were calculated using a simple linear regression




To compare the ability of the SCMGENE and PAM50 assays
to predict patient outcome, we performed Cox proportional
hazard regression analyses using the entire combined dataset
as provided by Haibe-Kains et al. [6]. In the multivariate
model (MVA), both predictors were found significantly
associated with distant metastasis-free survival (Table 1)
and the Luminals A and B segregation of the PAM50 assay
was found significantly associated with outcome, whereas
the ER?/HER2-/Low Proliferative and ER?/HER2-/
High Proliferative segregation of the SCMGENE predictor
was not. Conversely, distant metastasis-free survival dif-
ferences of the ER-/HER2- versus the ER?/HER2-/Low
Proliferative groups were found significant, whereas the
Basal-like versus Luminal A segregation was not.
To compare the amount of independent prognostic
information provided by each predictor, we estimated
the likelihood ratio statistic of each predictor in a model
that already included clinical–pathological variables (age,
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tumor size, treatment and nodal status) and the other pre-
dictor. The results revealed that the PAM50 subtypes
provide a larger amount of independent prognostic infor-
mation than the SCMGENE subtypes when using the entire
cohort of heterogeneously treated patients (Fig. 1A, B).
Similar results were observed when using the subset of
patients that did not receive adjuvant systemic therapy
(Fig. 1C, D), and in the subset of patients with HR?
tumors that received adjuvant tamoxifen-only (Fig. 1E, F).
Chemotherapy response prediction
To compare the ability of the PAM50 and SCMGENE assays
to predict response to chemotherapy, we evaluated the
MAQC2 (GSE20194) [21] dataset included in Haibe-Kains
et al. [6] analyses. This cohort is composed of 226 pre-
treatment samples with annotated response data (pCR vs.
RD) after neoadjuvant anthracycline/taxane-based chemo-
therapy (without trastuzumab for HER2? disease). As
shown in Table 2, although both assays predicted response in
univariate analysis, the PAM50 assay was the only one to
provide independent predictive information in the MVA
model.
Of note, the association of the PAM50 subtype with
response was strengthened when PAM50 subtyping of the
MAQC2 dataset was performed after median centering the
PAM50 genes/rows (Supplemental Table 1). In fact, we and
others have previously proposed median gene centering to
minimize technical bias and allow the correct identification
of the PAM50 intrinsic subtypes when appropriate repre-
sentation of ER-, ER?, and HER2? samples is available
[31, 32]. Median gene centering of the UNC337 dataset
before PAM50 or SCMGENE predictions also improved the
survival classifications (Supplemental Fig. 1).
Capturing the main biological diversity
Finally, to compare both predictors in terms of their ability to
capture the main biological diversity displayed by all genes
in a breast cancer microarray, we first combined 18 datasets
evaluated by Haibe-Kains et al. [6] and identified the two
Table 1 Distant metastasis-free survival Cox proportional hazards models of primary breast cancer patients
Variables Univariate analysis Multivariate analysis
HR Lower 95 % Upper 95 % p Value HR Lower 95 % Upper 95 % p Value
Age (cont. variable) 0.989 0.983 0.996 0.003 0.996 0.988 1.003 0.257
Node status 1.176 0.851 0.992 0.063 1.695 1.315 2.184 \0.001
Tumor size T2–T4 versus T0–T1 1.305 1.104 1.541 0.002 1.242 1.042 1.480 0.015
Treatment (yes vs. no) 0.973 0.845 1.121 0.707 0.547 0.428 0.700 \0.001
PAM50
Luminal A 1.0 – – – 1.0 – – –
Luminal B 1.797 1.503 2.149 \0.001 2.041 1.578 2.641 \0.001
HER2-E 2.677 2.120 3.380 \0.001 1.648 1.073 2.530 0.023
Basal-like 2.144 1.737 2.647 \0.001 1.312 0.812 2.121 0.268
Normal-like 1.073 0.670 1.718 0.769 1.024 0.572 1.835 0.936
Three-gene signature
ER?/HER2-/Low Prolif 1.0 – – – 1.0 – – –
ER?/HER2-/High Prolif 1.852 1.531 2.241 \0.001 1.153 0.882 1.508 0.297
HER2? 2.785 2.196 3.533 \0.001 1.588 1.053 2.395 0.028
ER-/HER2- 2.536 2.041 3.150 \0.001 1.762 1.095 2.835 0.020
HER2-E HER2-enriched, Prolif proliferation, HR hazard ratio
Fig. 1 Distant metastasis-free survival likelihood ratio statistics of
subtypes defined by the PAM50 or the SCMGENE predictors, after
accounting for clinical–pathological variables (age at diagnosis, nodal
status, treatment and tumor size). Models were first conditioned on
one predictor and the clinical–pathological variables, and then the
significance of the other was tested. (A–B) Entire combined dataset
(n = 2,008), (C–D) subset of patients that did not receive adjuvant
systemic therapy (n = 994), (E–F) subset of patients with HR?
tumors that received adjuvant tamoxifen-only (n = 491). Similar
results are obtained if a term for dataset is included in the model
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main principal components (PC1 and PC2). Compared to the
SCMGENE subtypes, the PAM50 subtypes explained sub-
stantially more variation in gene expression for both PC1 and
PC2 (Fig. 2a, b), with these components being especially
prominent for the separation of the Luminal A (or ER?/
HER2-/Low Proliferative) and Luminal B (or ER?/
HER2-/High Proliferative) subtypes. To confirm these
findings, we also evaluated all PCs in each normalized
dataset provided by Haibe-Kains et al. [6] and observed that
among 483 PCs significantly explained by either one of the
predictors, the PAM50 explained 2.27 times more indepen-
dent variation in expression than the SCMGENE assay.
Discussion
Our results presented here, using the same data provided by
Haibe-Kains et al. [6], suggest that (1) the SCMGENE and
the PAM50 predictors should not be considered the same in
terms of outcome prediction; (2) both provide independent
Table 2 pCR logistic regression models of the MAQC2 (GSE20194) [21] neoadjuvant breast cancer dataset
Variables N pCR rate (%) Univariate analysis Multivariate analysis
OR Lower 95 % Upper 95 % p Value OR Lower 95 % Upper 95 % p Value
Age (cont. variable) – – 1.0 0.95 1.01 0.169 – – – –
Tumor size
T0–T1 23 35 1.0 – – – 1.0 – – –
T2–T4 203 19 2.3 0.92 5.86 0.076 0.4 0.13 1.23 0.111
PAM50
Luminal A 66 3 1.0 – – – 1.0 – – –
Luminal B 66 9 3.2 0.62 16.47 0.164 5.2 0.68 37.97 0.108
HER2-E 28 46 23.5 5.25 105.36 \0.001 12.5 1.46 145.68 0.030
Basal-like 59 42 27.7 5.65 136.18 \0.001 25.3 2.64 255.95 0.005
Normal-like 7 0 0.0 0.00 – 0.988 0.0 0.00 – 0.988
Three-gene signature
ER?/HER2-/Low Prolif 52 4 1.0 – – – 1.0 – – –
ER?/HER2-/High Prolif 85 8 2.2 0.45 11.23 0.325 0.6 0.08 4.62 0.633
HER2? 24 50 25.0 4.93 126.80 \0.001 3.9 0.34 46.46 0.275
ER-/HER2- 65 38 15.6 3.49 69.93 \0.001 0.9 0.09 9.97 0.954
HER2-E HER2-enriched, Prolif proliferation, OR odds ratio
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Fig. 2 PC1 and PC2 loading plots of 3,316 samples using 18
Affymetrix and Agilent-based datasets taken from Haibe-Kains et al.
[6]. Samples colored based on the a SCMGENE calls, or b PAM50
subtype calls. PC1 and PC2 R2 values obtained from simple linear
regression models are shown. Only datasets with [50 % and \90 %
ER? tumors were included in this analysis. Blue Luminal A or ER?/
HER2-/Low Proliferative, light blue Luminal B or ER?/HER2-/
High Proliferative, pink HER2-enriched or HER2?, red Basal-like or
ER-/HER2-, green normal-like, black normal breast samples (only
present in the UNC337 dataset [29]). For the UNC337 dataset, we
colored samples based on the subtype calls obtained after median
centering as shown in Supplemental Fig. 1
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prognostic information; (3) the amount of prognostic
information provided by the PAM50 predictor is greater
than the information provided by the SCMGENE predictor;
and (4) the PAM50 assay is the only independent predictor
of neoadjuvant chemotherapy response.
A potential explanation of our findings is that the bio-
logical diversity of breast cancer is better captured using
the quantitative measurement of the 50 PAM50 gene set
compared to the 3 genes of the SCMGENE assay. This
finding is further supported by our previous data during the
PAM50 assay development, where the minimum number
of genes required to identify the intrinsic molecular sub-
types, as defined by subtype classifications based upon
the *1,900 intrinsic gene list with a 93 % accuracy, was
the final selected 50 genes [1]. In fact, gene sets with less
than 50 genes showed significantly worse accuracies, par-
ticularly for tumors of the Luminal B and HER2-enriched
subtypes (Supplemental Fig. 2). Importantly, only 33.3 %
(12/36) of all microarray datasets evaluated in Haibe-Kains
et al. [6] had all the PAM50 genes available, whereas
100 % of the datasets had all three genes of the SCMGENE
assay, thus highlighting another caveat of this study.
In total, these analyses show that a combination of ER,
HER2, and a single proliferation biomarker (i.e., AURKA)
is prognostic, but is suboptimal to capture the biological
diversity of breast cancers, which has similar implications
for the capture of this biological diversity using IHC-based
methods. Although a head-to-head comparison of both
assays in terms of their clinical utility might be warranted
in the future, our results suggest that classification of the
major and clinically relevant molecular subtypes is better
achieved using larger gene sets that capture a greater pro-
portion of the biological diversity of breast cancers.
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